Spatial and Single Cell Characterization of Breast Cancer Progression: Presenter Profile
Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.Source: SABCS Meeting News
Why Some Lung Tumors Respond Better to Targeted Therapies Than Others
In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.
Researchers Probe Why Vaccine Responses Differ From Person to Person
A team of researchers led by Yale School of Medicine’s Steven Kleinstein, PhD, is striving to understand why some people’s immune systems generate a robust protective response post-vaccination while others’ fail, and how this differs across vaccines. The team has published a series of new papers on its investigations.
Two Yale Pathology Faculty Among 12 Honored with 2022 Yale Faculty Innovation Awards
Two Yale Pathology professors were among 12 faculty members honored with 2022 Yale Faculty Innovation Awards, which recognize the significant contributions of Yale faculty who develop new technologies and launch startups that address global challenges.
Keith Choate, MD ’04, PhD ’01, Appointed Chair/Chief of Dermatology
Keith Choate, MD, PhD, will become chair of the Department of Dermatology and chief of Dermatology of Yale New Haven Hospital effective October 1, 2022. Choate will also work collaboratively with delivery network leadership to advance dermatological services across Yale New Haven Health System.
De Qué Trata la Inmunoterapia, un Tratamiento Que ha Mostrado Grandes Avances en la Lucha Contra el Cáncer
Este 22 de septiembre el Instituto de Investigación del Cáncer en Estados Unidos llevará a cabo una conferencia virtual en la que abordará varios temas sobre la inmunoterapia y sus beneficios para los pacientes con cáncer. De acuerdo con Kurt Schalper, profesor de la Universidad de Yale, el objetivo de dicha reunión es lograr que la comunidad hispana tenga acceso a información valiosa acerca de dicho tratamiento. | This September 22, the Institute for Cancer Research in the United States will hold a virtual conference in which it will address various topics about immunotherapy and its benefits for cancer patients. According to Kurt Schalper, a professor at Yale University, the objective of this meeting is to ensure that the Hispanic community has access to valuable information about said treatment.Source: UNIVISION
ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology
Madeline Mayday, BS, a fourth-year Experimental Pathology graduate student in the Laboratory of Diane Krause, MD, PhD, was recently awarded a 2022 National Institute of Diabetes and Digestive and Kidney Diseases Hematology Centers Program Type B Pilot and Feasibility grant
Marie Robert, MD, Jordan Pober, MD, PhD, Awarded POINTS Grant to Study Pathogenesis of Celiac Disease
Marie Robert, MD, Professor of Pathology and of Medicine (Digestive Diseases), and Jordan Pober, MD, PhD, the Bayer Professor of Translational Medicine and Professor of Immunobiology, Pathology, and Dermatology, have been awarded a grant from the Program for the Promotion of Interdisciplinary Team Science (POINTS) at Yale School of Medicine to study the Pathogenesis of Celiac Disease.
Cancer Research Institute To Host Second-Annual Spanish-Language Virtual Immunotherapy Patient Summit, Moderated By Ana Patricia Gámez, To Connect The U.S. Hispanic Cancer Community With Information That Can Save Lives
The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system's power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient Summit in Spanish on September 22, 2022, 2-5 p.m. ET. This free virtual event, moderated by TV Host and Entrepreneur Ana Patricia Gámez, and presented completely in Spanish, will connect Hispanic cancer patients and caregivers with groundbreaking research updates from leading immunotherapy experts driving scientific breakthroughs and advancements that impact patient care.Source: PR Newswire
Yale Cancer Center Researchers Awarded Grants by Breast Cancer Research Foundation
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
How Studying Cellular Senescence Can Help Researchers Learn to Delay Aging
Chronic inflammation, one of the major hallmarks of aging, is thought to be partly caused by senescent cells that may accumulate in older individuals. Now, Yale researchers have received a grant from the National Institutes of Health (NIH) Common Fund’s Cellular Senescence Network Program (SenNet) to study these specialized cells.
Biosimilar-to-Biosimilar Switches Deemed Safe and Effective, Systematic Review Reveals
Switching from one biosimilar medication to another is safe and effective, a new systematic review indicates, even though this clinical practice is not governed by current health authority regulations or guidance. "No reduction in effectiveness or increase in adverse events was detected in biosimilar-to-biosimilar switching studies conducted to date," the review's authors note in their study, published online July 26 in BioDrugs. "The possibility of multiple switches between biosimilars of the same reference biologic is already a reality, and these types of switches are expected to become more common in the future. …although it is not covered by current health authority regulations or guidance," add the authors, led by Hillel P. Cohen, PhD, executive director of scientific affairs at Sandoz, a division of Novartis.Source: Medscape